4.7 Article

Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action

期刊

AMERICAN JOURNAL OF CHINESE MEDICINE
卷 49, 期 7, 页码 1645-1666

出版社

WORLD SCIENTIFIC PUBL CO PTE LTD
DOI: 10.1142/S0192415X21500762

关键词

Berberine; Herbal Medicine; Heart; Cardiometabolic Disease; Mechanism; Review

资金

  1. National Natural Science Foundation of China [81973612]
  2. Shanghai Municipal Health Commission [ZK2019A11, ZK2019A10]

向作者/读者索取更多资源

Berberine has shown pleiotropic therapeutic effects against cardiometabolic diseases, involving mechanisms such as combating inflammation and oxidative stress, regulating electrical signals, promoting energy metabolism, modifying gut microbiota, and interacting with non-coding RNAs targeting multiple signaling pathways.
Berberine is an alkaloid from several medicinal plants originally used to treat diarrhea and dysentery as a traditional Chinese herbal medicine. In recent years, berberine has been discovered to exhibit a wide spectrum of biological activities in the treatment of diverse diseases ranging from cancer and neurological dysfunctions to metabolic disorders and heart diseases. This review article summarizes the clinical practice and laboratory exploration of berberine for the treatment of cardiometabolic and heart diseases, with a focus on the novel insights and recent advances of the underlying mechanisms recognized in the past decade. Berberine was found to display pleiotropic therapeutic effects against dyslipidemia, hyperglycemia, hypertension, arrhythmia, and heart failure. The mechanisms of berberine for the treatment of cardiometabolic disease involve combating inflammation and oxidative stress such as inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) activation, regulating electrical signals and ionic channels such as targeting human ether-a-go-go related gene (hERG) currents, promoting energy metabolism such as activating adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, modifying gut microbiota to promote transforming of berberine into its intestine-absorbable form, and interacting with non-coding RNAs via targeting multiple signaling pathways such as AMPK, mechanistic target of rapamycin (mTOR), etc. Collectively, berberine appears to be safe and well-tolerated in clinical practice, especially for those who are intolerant to statins. Knowledge from this field may pave the way for future development of more effective pharmaceutical approaches for managing cardiometabolic risk factors and preventing heart diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据